Metastatic Uveal Melanoma clinical trials

Explore recruiting metastatic uveal melanoma clinical trials.

Recruiting metastatic uveal melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Uveal Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma

Germany, Italy, France, Spain, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

Neoadjuvant Tebentafusp in Patients with Metastatic Uveal Melanoma

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma

Spain, Italy, Poland, Germany, Belgium, France +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

A phase II, monocentric, single arm trial evaluating the efficacy and safety of Pembrolizumab in combination with Lenvatinib in metastatic Uveal MElanoma patients

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II stUdy of ALoCelyvir in patientS with mEtastaticUveal Melanoma (PULSE-UM)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Uveal Melanoma trials by city

Metastatic Uveal Melanoma in Toronto Metastatic Uveal Melanoma in Vancouver Metastatic Uveal Melanoma in Montreal Metastatic Uveal Melanoma in Calgary Metastatic Uveal Melanoma in Edmonton Metastatic Uveal Melanoma in Ottawa Metastatic Uveal Melanoma in Winnipeg Metastatic Uveal Melanoma in Quebec City Metastatic Uveal Melanoma in Hamilton Metastatic Uveal Melanoma in Kitchener Metastatic Uveal Melanoma in London Metastatic Uveal Melanoma in Halifax Metastatic Uveal Melanoma in New York Metastatic Uveal Melanoma in Los Angeles Metastatic Uveal Melanoma in Chicago Metastatic Uveal Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease